Finance

Lists
Why is TXG up ၄.၃၆%?
Dive Deeper
TXG:NASDAQ
10X Genomics Inc
၈၀.၆၅ US$
+၄.၃၆%
(+၃.၃၇) 1D
၈၁.၀၅ US$
+၀.၅၀% (+၀.၄၀)
After hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TXG...
Open
၇၈.၆၀ US$
High
၈၅.၁၂ US$
Low
၇၈.၅၂ US$
Mkt. cap
ဋေ ၁.၀၅ ထ
Avg. vol.
၃.၄၃ သန်း
Volume
၃.၆၉ သန်း
52-wk high
၁၀၂.၈၁ US$
52-wk low
၁၁.၁၆ US$
EPS
-၀.၅၉ US$
Beta
၁.၉၉
Shares outstanding
၁၂.၀၂ ကုဋေ
No. of employees
၁ ထောင်
Open
၇၈.၆၀ US$
High
၈၅.၁၂ US$
Low
၇၈.၅၂ US$
Mkt. cap
ဋေ ၁.၀၅ ထ
Avg. vol.
၃.၄၃ သန်း
Volume
၃.၆၉ သန်း
52-wk high
၁၀၂.၈၁ US$
52-wk low
၁၁.၁၆ US$
EPS
-၀.၅၉ US$
Beta
၁.၉၉
Shares outstanding
၁၂.၀၂ ကုဋေ
No. of employees
၁ ထောင်
News stories
From web sources and news partners
https://www.dars.gov.et/
https://www.dars.gov.et/
·
ပြီးခဲ့သည့် ၁ ပတ်
10x Genomics (TXG) Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus - ROIC Trend Report
Profile
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. Wikipedia
About 10X Genomics Inc
CEOSerge Saxonov
Employees၁.၁၈ ထောင်
Founded၂၀၁၂
HeadquartersPleasanton, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Website10xgenomics.com
Analyst ratings
Based on 16 analysts giving stock ratings to TXG in the past 3 months
Buy
Buy
7
Hold
9
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TXG in the last 3 months.
Highest
Current ၈၀.၆၅ US$
၁၁၀.၀၀ US$ (+၃၆.၃၉%)
Average
၆၈.၂၀ US$ (-၁၅.၄၄%)
Lowest
၄၀.၀၀ US$ (-၅၀.၄၀%)
Analyst
Recommendation
Action
Price target
Projected
Date
‏Avantika Dhabaria‏
Bank of America Securities
Hold
Maintained
၈၀.၀၀ US$
-၀.၈%
10/09/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
၈၀.၀၀ US$
-၀.၈%
10/09/2026
Luke Sergott
Barclays
Buy
Maintained
၁၁၀.၀၀ US$
+၃၆.၄%
10/07/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/29/2026
Puneet Souda
Leerink Partners
Hold
Maintained
၉၀.၀၀ US$
+၁၁.၆%
09/29/2026
David Westenberg
Piper Sandler
Hold
Reiterated
၈၀.၀၀ US$
-၀.၈%
09/28/2026
Unknown Analyst
Argus Research
Buy
Initiated
၁၁၀.၀၀ US$
+၃၆.၄%
09/28/2026
John Eade
Argus Research
Buy
Initiated
၁၁၀.၀၀ US$
+၃၆.၄%
09/25/2026
Unknown Analyst
UBS
Hold
Initiated
၆၈.၀၀ US$
-၁၅.၇%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
၆၈.၀၀ US$
-၁၅.၇%
09/09/2026
Dan Leonard
RBC Capital
Hold
Initiated
၇၀.၀၀ US$
-၁၃.၂%
09/01/2026
Unknown Analyst
Stephens
Buy
Reiterated
၆၅.၀၀ US$
-၁၉.၄%
08/12/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
၅၀.၀၀ US$
-၃၈%
08/10/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
၅၀.၀၀ US$
-၃၈%
08/11/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
၆၀.၀၀ US$
-၂၅.၆%
08/10/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Reiterated
၄၀.၀၀ US$
-၅၀.၄%
08/10/2026
Tycho Peterson
Jefferies
Buy
Reiterated
၅၃.၀၀ US$
-၃၄.၃%
08/07/2026
Patrick B Donnelly
Citi
Hold
Maintained
၅၀.၀၀ US$
-၃၈%
08/07/2026
‏Brendan Digan‏
Citi
Hold
Maintained
၅၀.၀၀ US$
-၃၈%
08/07/2026
Daniel Brennan
TD Cowen
Hold
Maintained
၄၇.၀၀ US$
-၄၁.၇%
07/15/2026
Justin Bowers
Deutsche Bank
Hold
Maintained
၂၃.၀၀ US$
-၇၁.၅%
05/08/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
၀.၀၃ US$ / -၀.၀၂ US$
+၂၅၈.၃၇%beat
Revenue / Est. (USD)
၁၅.၁၀ ကုဋေ / ၁၄.၆၆ ကုဋေ
+၃.၀၁%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၁၄.၉၀ ကုဋေ
၁၆.၆၀ ကုဋေ
၁၅.၀၈ ကုဋေ
၁၅.၁၀ ကုဋေ
Cost of goods sold
၄.၈၇ ကုဋေ
၅.၂၉ ကုဋေ
၄.၄၇ ကုဋေ
၃.၈၅ ကုဋေ
Cost of revenue
၄.၈၇ ကုဋေ
၅.၂၉ ကုဋေ
၄.၄၇ ကုဋေ
၃.၈၅ ကုဋေ
Research and development expenses
၅.၇၂ ကုဋေ
၅.၅၈ ကုဋေ
၅.၆၈ ကုဋေ
၅.၆၈ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၇.၄၇ ကုဋေ
၇.၃၀ ကုဋေ
၆.၆၄ ကုဋေ
၇.၈၇ ကုဋေ
Operating expense
၁၃.၁၈ ကုဋေ
၁၂.၈၈ ကုဋေ
၁၂.၃၂ ကုဋေ
၁၃.၅၅ ကုဋေ
Total operating expenses
၁၈.၀၅ ကုဋေ
၁၈.၁၇ ကုဋေ
၁၆.၇၉ ကုဋေ
၁၇.၄၀ ကုဋေ
Operating income
-၃.၁၅ ကုဋေ
-၁.၅၆ ကုဋေ
-၁.၇၀ ကုဋေ
-၂.၃၀ ကုဋေ
Other non operating income
၅.၃၈ သိန်း
-၃.၀၄ သန်း
-၇.၂၀ သောင်း
-၃.၄၉ သန်း
EBT including unusual items
-၂.၈၂ ကုဋေ
-၁.၅၂ ကုဋေ
-၁.၂၈ ကုဋေ
-၁.၈၆ ကုဋေ
EBT excluding unusual items
-၂.၆၄ ကုဋေ
-၁.၂၄ ကုဋေ
-၁.၂၉ ကုဋေ
-၂.၂၀ ကုဋေ
Income tax expense
-၇.၃၃ သိန်း
၁.၀၆ သန်း
၆.၂၃ သိန်း
-၇.၁၄ သိန်း
Effective tax rate
၂.၆၀%
-၆.၉၇%
-၄.၈၅%
၃.၈၃%
Other operating expenses
-
-
-
-
Net income
-၂.၇၅ ကုဋေ
-၁.၆၃ ကုဋေ
-၁.၃၅ ကုဋေ
-၁.၇၉ ကုဋေ
Net profit margin
-၁၈.၄၄%
-၉.၇၉%
-၈.၉၃%
-၁၁.၈၇%
Earnings per share
-၀.၀၂
၀.၀၇
၀.၀၇
၀.၀၃
Interest and investment income
၅.၂၀ သန်း
၆.၈၉ သန်း
၅.၀၁ သန်း
၄.၈၀ သန်း
Interest expense
-
-
-
-
Net interest expenses
၅.၂၀ သန်း
၆.၈၉ သန်း
၅.၀၁ သန်း
၄.၈၀ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၁၂ ကုဋေ
-၅.၅၈ သန်း
-၇.၀၉ သန်း
-၁.၃၃ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ